MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Strona główna・Stock List・Intra-Cellular Therapies Inc

Intra-Cellular Therapies Inc

Closed

SectorHealthcare

Buy Sell

Overview

Share price change

24h

Current

Min

Max

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	-0.79% downside

Market Stats
By TradingEconomics
Market Cap	95M 12B
Previous open	0
Previous close	0

News Sentiment

By Acuity

50%

157 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

131.5 / 131.92 Support & Resistance

Intra-Cellular Therapies Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

13 sty 2025, 12:11 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Intra-Cellular in $14.6 Billion Deal

13 sty 2025, 11:40 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson in Talks to Acquire Intra-Cellular Therapies, Says Bloomberg

14 mar 2025, 09:30 UTC

Top News

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

22 sty 2025, 14:09 UTC

Top News

Earnings

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

22 sty 2025, 11:22 UTC

Top News

Earnings

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth -- Barrons.com

13 sty 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

J&J Announces A Splashy $14.6 Billion Deal, While Lilly Tacks On A Cancer Drug -- IBD

13 sty 2025, 20:12 UTC

Top News

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- Update

13 sty 2025, 16:18 UTC

Top News

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal -- WSJ

13 sty 2025, 15:57 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Bets Big on Mental Health Drugs With $14.6 Billion Intra-Cellular Deal -- Barrons.com

13 sty 2025, 14:10 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal -- IBD

13 sty 2025, 12:25 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson in $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 sty 2025, 11:57 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Confirms $14.6 Billion Deal to Buy Biotech Intra-Cellular -- Barrons.com

13 sty 2025, 11:56 UTC

Top News

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Acquire Intra-Cellular in $14.6B Deal

13 sty 2025, 11:45 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Intra-Cellular's Clinical-Stage Pipeline Has Best-In-Disease Potential in Generalized Anxiety Disorder, Alzheimer's Treatments >JNJ

13 sty 2025, 11:43 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Caplyta Solidifies Sales Above Analyst Expectations Through Remainder of Decade>JNJ

13 sty 2025, 11:43 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Caplyta Has Potential of Over $5 Billion in Peak Yr Sales >JNJ

13 sty 2025, 11:42 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Purchases Intra-Cellular for $132/Shr in Cash, or About $14.6B >JNJ

13 sty 2025, 11:41 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: SNDA Submitted to FDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder >JNJ

13 sty 2025, 11:40 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Acquisition Includes CaplytaTreatment for Bipolar I and II Depression, Schizophrenia >JNJ

13 sty 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: Deal Adds Intra-Cellular's Caplyta Depression Drug >JNJ ITCI

13 sty 2025, 11:32 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson: To Maintain Strong Balance Sheet, Continue to Support Capital-Allocation Priorities >JNJ

13 sty 2025, 11:32 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson To Fund Transaction With Cash on Hand, Debt >JNJ ITCI

13 sty 2025, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Buy Intra-Cellular Therapies for About $14.6 Billion >JNJ ITCI

13 sty 2025, 11:31 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson to Buy Intra-Cellular Therapies for $132/Share in Cash >JNJ ITCI

13 sty 2025, 11:30 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Strengthens Neuroscience Leadership With Acquisition Of Intra-Cellular Therapies, Inc. >JNJ ITCI

13 sty 2025, 10:55 UTC

Acquisitions, Mergers, Takeovers

This Stock Is Soaring Amid Johnson & Johnson Takeover Report -- Barrons.com

13 sty 2025, 10:41 UTC

Acquisitions, Mergers, Takeovers

This Stock Is Soaring Amid J&J Takeover Report. What to Know. -- Barrons.com

Peer Comparison

Price change

Intra-Cellular Therapies Inc Forecast

Price Target

By TipRanks

-0.79% downside

12 Months Forecast

Average 130.83 USD -0.79%

High 132 USD

Low 118 USD

Based on 13 Wall Street analysts offering 12 month price targets forIntra-Cellular Therapies Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

13 ratings

Buy

Hold

Sell

Based on 13 analysts giving stock ratings to Intra-Cellular Therapies Inc - Dist in the past 3 months.

Technical Score

By Trading Central

131.5 / 131.92Support & Resistance

There is one bullish event.

There are no events.

Sentiment

By Acuity

157 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Intra-Cellular Therapies Inc

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.